The first step in the activation of the prohormone, thyroxine (T4), is its 5' monodeiodination to T3, catalyzed by the types 1 and 2 iodothyronine deiodinase. Type 3 deiodinase (03) catalyzed removal of an inner ring iodine inactivating T4 or T3. These three enzymes have two common features; they are integral membrane proteins and all have the rare amino acid selenocysteine in their active center to serve as the iodine acceptor. They confer two general advantages to the regulation of thyroid hormone action. First, during embryological development, activation and inactivation of thyroid hormone is programmed to occur at specific times in specific cells to allow either induction or repression of thyroid hormone-dependent gene expression. Second, throughout life, the important role of D2 in the hypothalamic-pituitary-thyroid axis permits the terrestrial vertebrate to adapt to iodine deficiency by monitoring the concentration of T4 in the circulation. This permits increases in TRH and TSH secretion, long before the concentrations of the active hormone, T3, decrease. In humans, it has long been assumed that D1, present in high concentrations in the liver and kidney, is the major source of circulating T3. More recent analyses of D2 expression patterns together with older in vivo results suggest that this is not the case and that most plasma T3 in humans probably derives from the activation of T4 by D2. This enzyme is widely expressed in humans, but not in rodents. The present proposal will focus on 3 aspects of the molecular physiology of the deiodinases.
Specific Aim I will analyze the causes of the unique topology and subcellular localizations of D1, 02 and D3 in the cell using confocal microscopy and cell biological techniques.
Specific Aim II will employ cells expressing endogenous or recombinant D1 and 02 to understand why D2 is the major enzyme catalyzing extrathyroidal T3 production in humans. We also will determine why the T3 produced by D2-catalyzed T4 5'-deiodination enters the nucleus whereas that generated by D1 does not.
Specific Aim I ll will address the issue of the active form of the three enzymes. Are they homodimers or do they interact with other proteins? We will also analyze the functional effects of this interaction. These studies will thus address the basic mechanisms by which thyroid hormone activation and inactivation are regulated in both normal and pathological states.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK036256-19
Application #
6546714
Study Section
Endocrinology Study Section (END)
Program Officer
Margolis, Ronald N
Project Start
1985-01-01
Project End
2007-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
19
Fiscal Year
2003
Total Cost
$406,550
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Luongo, Cristina; Martin, Cecilia; Vella, Kristen et al. (2015) The selective loss of the type 2 iodothyronine deiodinase in mouse thyrotrophs increases basal TSH but blunts the thyrotropin response to hypothyroidism. Endocrinology 156:745-54
Dentice, Monica; Marsili, Alessandro; Zavacki, Annmarie et al. (2013) The deiodinases and the control of intracellular thyroid hormone signaling during cellular differentiation. Biochim Biophys Acta 1830:3937-45
Aguayo-Mazzucato, Cristina; Zavacki, Ann Marie; Marinelarena, Alejandra et al. (2013) Thyroid hormone promotes postnatal rat pancreatic ýý-cell development and glucose-responsive insulin secretion through MAFA. Diabetes 62:1569-80
Zhang, Yongzhao; Li, Yingxia; Niepel, Michele W et al. (2012) Targeted deletion of thioesterase superfamily member 1 promotes energy expenditure and protects against obesity and insulin resistance. Proc Natl Acad Sci U S A 109:5417-22
Larsen, P Reed; Zavacki, Ann Marie (2012) The role of the iodothyronine deiodinases in the physiology and pathophysiology of thyroid hormone action. Eur Thyroid J 1:232-242
Zhu, Bo; Shrivastava, Ashutosh; Luongo, Cristina et al. (2012) Catalysis leads to posttranslational inactivation of the type 1 deiodinase and alters its conformation. J Endocrinol 214:87-94
Patwari, Parth; Emilsson, Valur; Schadt, Eric E et al. (2011) The arrestin domain-containing 3 protein regulates body mass and energy expenditure. Cell Metab 14:671-83
Marsili, Alessandro; Sanchez, Edith; Singru, Praful et al. (2011) Thyroxine-induced expression of pyroglutamyl peptidase II and inhibition of TSH release precedes suppression of TRH mRNA and requires type 2 deiodinase. J Endocrinol 211:73-8
Wajner, Simone Magagnin; Goemann, Iuri Martin; Bueno, Ana Laura et al. (2011) IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. J Clin Invest 121:1834-45
Roh, Michael H; Jo, Vickie Y; Stelow, Edward B et al. (2011) The predictive value of the fine-needle aspiration diagnosis ""suspicious for a follicular neoplasm, hurthle cell type"" in patients with hashimoto thyroiditis. Am J Clin Pathol 135:139-45

Showing the most recent 10 out of 91 publications